FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2124632950> ?p ?o ?g. }

• W2124632950 endingPage "1722" @default.
• W2124632950 startingPage "1722" @default.
• W2124632950 abstract "Back to table of contents Previous article Next article Letter to the EditorFull AccessDr. Rubin RepliesROBERT T. RUBIN, M.D., Ph.D., ROBERT T. RUBINSearch for more papers by this author, M.D., Ph.D., Pittsburgh, Pa.Published Online:1 Sep 2004https://doi.org/10.1176/appi.ajp.161.9.1722AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail To the Editor: I appreciate the opportunity to reply to several issues raised by Dr. Rothschild. First is my taking him to task for nondisclosure of a financial conflict of interest. When I wrote my review of Dr. Rothschild’s chapter, he had declared “a financial interest in Corcept Therapeutics” in a published article (1). Only recently did he clarify that “in the past, he has been a consultant to and received research grants from Corcept Therapeutics” (2). If Dr. Rothschild had provided a similar statement in the chapter in question, this issue would not have arisen.Second is whether financial disclosures should be required in book chapters. I believe they should. Financial disclosure is a major issue now; e.g., following a recent exposé of the nondisclosure of several major financial conflicts in a review of depression treatments (3), the Nature Publishing Group extended its disclosure requirement to review articles (4). Other journals have expanded their disclosure policies to cover all published material, and public interest groups have lent their voice in support (5). Nevertheless, violations continue to surface; e.g., the controversy over nondisclosure in an article in the Lancet suggesting a link between measles-mumps-rubella vaccinations and pervasive developmental disorder in children (6). Even full disclosure, however, is not a panacea (7).Third is the questionable efficacy of mifepristone in psychotic depression in contrast to Dr. Rothschild’s statement of its use in “rapidly reversing psychotic major depression.” In the two published studies on this issue, there was no significant drug effect (1, 8). In the first study (8), two placebo cells were eliminated because they were considered a drug carryover effect, and an independent-samples analysis apparently was performed, even though the data were paired (subjects were their own control subjects). My independent, paired-data analysis yielded a clearly nonsignificant difference. In the second study, no statistical analysis at all was presented. My analysis of those outcome data again yielded a clearly nonsignificant difference. As well, the April 2004 initial public offering filed with the Securities and Exchange Commission by Corcept Therapeutics (9) indicates that even in large double-blind trials, only a small number of patients became asymptomatic, with no significant difference between drug and placebo. Does this medication, then, warrant the paean of “ECT in a bottle” (10)?References1. Belanoff JK, Rothschild AJ, Cassidy F, DeBattista C, Baulieu EE, Schold C, Schatzberg AF: An open label trial of C-1073 (miferistone) for psychotic major depression. Biol Psychiatry 2002; 52:386–392Crossref, Medline, Google Scholar2. Bell MA, Rothschild AJ: Psychotic depression. Curr Psychiatry 2004; 3:54–63Google Scholar3. Carroll BJ, Rubin RT: Editorial policies on financial disclosure. Nat Neurosci 2003; 6:999–1000Crossref, Medline, Google Scholar4. Financial disclosure for review authors (editorial). Nat Neurosci 2003; 6:997Crossref, Medline, Google Scholar5. Jacobson MF, Sharpe VA: Editorial policies on financial disclosure. Nat Neurosci 2003; 6:1001Crossref, Medline, Google Scholar6. Horton R: A statement by the editors of the Lancet. Lancet 2004; 363:820–821Crossref, Medline, Google Scholar7. Horton R: The dawn of McScience. New York Review of Books, March 11, 2004Google Scholar8. Belanoff JK, Flores BH, Kalezhan M, Sund B, Schatzberg AF: Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmacol 2001; 21:516–521Crossref, Medline, Google Scholar9. Securities and Exchange Commission Form s-1 Registration Statement Under the Securities Act of 1933: Corcept Therapeutics Incorporated. http://www.sec.gov/archives/edgar/data/1088856/000119312504018487/ds1.htm#toc73454_9Google Scholar10. Gelenberg A: Mifepristone (RU486) for psychotic major depression. Biol Ther Psychiatry, Jan 2003Google Scholar FiguresReferencesCited byDetailsCited ByDepression and Anxiety Disorders17 December 2021Depression and anxiety8 March 2013Trends in Endocrinology & Metabolism, Vol. 17, No. 10 Volume 161Issue 9 September 2004Pages 1722-1722 Metrics PDF download History Published online 1 September 2004 Published in print 1 September 2004" @default.
• W2124632950 created "2016-06-24" @default.
• W2124632950 creator A5004369157 @default.
• W2124632950 date "2004-09-01" @default.
• W2124632950 modified "2023-09-23" @default.
• W2124632950 title "Dr. Rubin Replies" @default.
• W2124632950 doi "https://doi.org/10.1176/appi.ajp.161.9.1722" @default.
• W2124632950 hasPublicationYear "2004" @default.
• W2124632950 type Work @default.
• W2124632950 sameAs 2124632950 @default.
• W2124632950 citedByCount "3" @default.
• W2124632950 countsByYear W21246329502021 @default.
• W2124632950 crossrefType "journal-article" @default.
• W2124632950 hasAuthorship W2124632950A5004369157 @default.
• W2124632950 hasConcept C151719136 @default.
• W2124632950 hasConcept C15744967 @default.
• W2124632950 hasConcept C17744445 @default.
• W2124632950 hasConcept C199539241 @default.
• W2124632950 hasConcept C2777276634 @default.
• W2124632950 hasConcept C2781350838 @default.
• W2124632950 hasConceptScore W2124632950C151719136 @default.
• W2124632950 hasConceptScore W2124632950C15744967 @default.
• W2124632950 hasConceptScore W2124632950C17744445 @default.
• W2124632950 hasConceptScore W2124632950C199539241 @default.
• W2124632950 hasConceptScore W2124632950C2777276634 @default.
• W2124632950 hasConceptScore W2124632950C2781350838 @default.
• W2124632950 hasIssue "9" @default.
• W2124632950 hasLocation W21246329501 @default.
• W2124632950 hasOpenAccess W2124632950 @default.
• W2124632950 hasPrimaryLocation W21246329501 @default.
• W2124632950 hasRelatedWork W1584414823 @default.
• W2124632950 hasRelatedWork W2017028543 @default.
• W2124632950 hasRelatedWork W2389403288 @default.
• W2124632950 hasRelatedWork W2475108818 @default.
• W2124632950 hasRelatedWork W2748952813 @default.
• W2124632950 hasRelatedWork W2899084033 @default.
• W2124632950 hasRelatedWork W2970188234 @default.
• W2124632950 hasRelatedWork W3005331246 @default.
• W2124632950 hasRelatedWork W3043929364 @default.
• W2124632950 hasRelatedWork W4234227429 @default.
• W2124632950 hasVolume "161" @default.
• W2124632950 isParatext "false" @default.
• W2124632950 isRetracted "false" @default.
• W2124632950 magId "2124632950" @default.
• W2124632950 workType "article" @default.